Long-acting injectable naltrexone for the treatment of alcohol dependence (Q36972683)

17 August 2017

1 reference

title

Long-acting injectable naltrexone for the treatment of alcohol dependence (English)

1 reference

17 August 2017

0 references

Paolo Mannelli

1

1 reference

17 August 2017

Kathleen Peindl

series ordinal

2

1 reference

17 August 2017

Prakash S Masand

series ordinal

3

1 reference

17 August 2017

Ashwin A Patkar

series ordinal

4

1 reference

17 August 2017

1 October 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

1265-1277

1 reference

17 August 2017

10

1 reference

Assessing the burden of disease in the United States using disability-adjusted life years

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Clinical practice. Unhealthy alcohol use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Recovery from DSM-IV alcohol dependence: United States, 2001-2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Treatment of Alcohol Abuse: An Evidence‐Based Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Barriers to the use of medications to treat alcoholism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Diabetic patients' alcohol use and quality of life: relationships with prescribed treatment compliance among older males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Predictors of compliance with naltrexone among alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Naltrexone and pharmacy benefit management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Advances in the pharmacotherapy of alcoholism: challenging misconceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

21 January 2018

Opioids and alcoholism

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Measures of clinical significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Adverse effects of oral naltrexone: analysis of data from two clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Naltrexone and problems in pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Trends in the adoption of medications for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Naltrexone and buprenorphine combination in the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

The effect of opioid antagonism on food intake behavior and body weight in a biobehavioral model of obese binge eating

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Smoking cessation guidelines for health professionals: an update. Health Education Authority

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Opioid Antagonists in the Treatment of Impulse-Control Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

Using stated preference and revealed preference modeling to evaluate prescribing decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.10.1265

10.1586/14737175.7.10.1265

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference